Evidence map›Paper›PMID 29692728›Full record

ReviewFrontiers in pharmacology2018

Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Ágatha Oliveira-Giacomelli, Yahaira Naaldijk, Laura Sardá-Arroyo, Maria C B Gonçalves, Juliana Corrêa-Velloso, Micheli M Pillat, Héllio D N de Souza, Henning Ulrich

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Microglia in Neurodegenerative Events-An Initiator or a Significant Other?International journal of molecular sciences · 2021
    Review
  13. Review
  14. Review
  15. Article
  16. P2XFrontiers in cellular neuroscience · 2021
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ágatha Oliveira-GiacomelliDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Yahaira NaaldijkDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Laura Sardá-ArroyoDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Maria C B GonçalvesDepartment of Neurology and Neuroscience, Medical School, Federal University of São Paulo, São Paulo, Brazil.
Juliana Corrêa-VellosoDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Micheli M PillatDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Héllio D N de SouzaDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Henning UlrichDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRUniversidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since proving adenosine triphosphate (ATP) functions as a neurotransmitter in neuron/glia interactions, the purinergic system has been more intensely studied within the scope of the central nervous system. In neurological disorders with associated motor symptoms, including Parkinson's disease (PD), motor neuron diseases (MND), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington's Disease (HD), restless leg syndrome (RLS), and ataxias, alterations in purinergic receptor expression and activity have been noted, indicating a potential role for this system in disease etiology and progression. In neurodegenerative conditions, neural cell death provokes extensive ATP release and alters calcium signaling through purinergic receptor modulation. Consequently, neuroinflammatory responses, excitotoxicity and apoptosis are directly or indirectly induced. This review analyzes currently available data, which suggests involvement of the purinergic system in neuro-associated motor dysfunctions and underlying mechanisms. Possible targets for pharmacological interventions are also discussed.

Indexed as

amyotrophic lateral sclerosis (ALS)ataxiaHuntington's diseasemultiple sclerosisneurodegenerationParkinson's diseasepurinergic receptorsrestless leg syndrome

Identifiers

PMID29692728
PMCPMC5902708
OpenAlexW2796748561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.